微生物群移植疗法在肺动脉高压中是安全可行的。
Microbiota Transplant Therapy Is Safe and Feasible in Pulmonary Arterial Hypertension.
作者信息
Moutsoglou Daphne, Blake Madelyn, Belhasan Dina C, Peichel Gretchen, Vang Brenda M, Weir E Kenneth, Lopez Sharon, Prins Kurt W, Kabage Amanda J, Prisco Sasha Z, Kremer Benjamin P, Khoruts Alexander, Thenappan Thenappan
机构信息
Gastroenterology Section, Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota, USA; Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Division of Cardiovascular Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
出版信息
JACC Basic Transl Sci. 2025 Aug 12;10(9):101347. doi: 10.1016/j.jacbts.2025.101347.
Pulmonary arterial hypertension (PAH) is a complex inflammatory disease that the gut microbiome likely contributes to and may be a potential therapeutic avenue for nontoxically improving outcomes. Here, we show that microbiota transplant therapy (MTT) is safe and feasible. The MTT regimen achieves only modest levels of donor microbiota engraftment but is accompanied by a transient reduction in circulating pro-inflammatory cytokines. These findings of decreased systemic inflammation with only modest donor engraftment support the potential of MTT as a novel treatment for PAH. (Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study; NCT04884971).
肺动脉高压（PAH）是一种复杂的炎症性疾病，肠道微生物群可能与之相关，并且可能是一种无毒改善预后的潜在治疗途径。在此，我们表明微生物群移植疗法（MTT）是安全可行的。MTT方案仅实现了适度水平的供体微生物群植入，但伴随着循环促炎细胞因子的短暂减少。这些仅伴有适度供体植入的全身炎症减轻的发现支持了MTT作为PAH新型治疗方法的潜力。（肺动脉高压的微生物群移植疗法：早期安全性和可行性研究；NCT04884971）
Zotero 插件